SCHEMBL28607609

SCHEMBL28607609

CC(CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1)OC(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.47
CA2 P00918 5/20 0.47
F2 P00734 2/20 0.47
PRSS1 P07477 2/20 0.47
PRSS2 P07478 2/20 0.47
PRSS3 P35030 2/20 0.47
MMP1 P03956 2/20 0.47
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
MMP13 P45452 2/20 0.47
MMP8 P22894 1/20 0.47
CA12 O43570 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31234771 0.82 CA2 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL27166746 0.79 CA2 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL27166753 0.79 CA2 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL1547978 0.79 ALDH1A1 (0.61) CA1CA2MMP1MMP2MMP9
Acetic Acid SCHEMBL8120218 0.79 ALDH1A1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL28614173 0.78 MMP2 (0.53) CA1CA2F2PRSS1PRSS2
SCHEMBL28614175 0.78 MMP2 (0.53) CA1CA2F2PRSS1PRSS2
Hydrochloric Acid SCHEMBL7362391 0.78 ALDH1A1 (0.59) CA1CA2MMP1MMP2MMP9
SCHEMBL21994408 0.77 POLB (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL30800487 0.76 CA2 (0.67) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335081-A Targeted plasma protein degradation 诺华股份有限公司 2022-11-11 CN disclosed
CN-113166101-A Cyclic pentameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders 诺华股份有限公司 2021-07-23 CN disclosed